Envoy Medical, Inc. Form 8-K Summary
Business context and reporting period
Filed October 5, 2023, reporting events occurring primarily on September 29, 2023. Formerly Anzu Special Acquisition Corp. I, the company completed its business combination with Envoy Medical Corporation and ceased to be a shell company. Envoy develops medical-device products; this filing primarily documents the transaction, corporate structure, securities issuances, and post-closing governance rather than current-period operating results.
Key financial and capitalization metrics
- Holders of 2,386,294 Anzu Class A shares redeemed their shares for approximately $25.0 million, or approximately $10.46 per share.
- The sponsor and affiliates purchased 1,000,000 Series A preferred shares in a private placement at $10.00 per share, generating aggregate stated consideration of $10.0 million.
- The holder of the Envoy Bridge Note received 1,000,000 Series A preferred shares in connection with the closing; the filing states aggregate consideration of $10.0 million for this issuance, but does not characterize it as new cash proceeds.
- Immediately after closing, the company had 19,549,982 shares of common stock, 4,500,000 Series A preferred shares, and 14,166,666 warrants outstanding.
- Each warrant is exercisable for one common share at $11.50 per share.
- Series A preferred shares have a stated conversion price of $11.50 per common share, subject to customary adjustments.
- The filing does not provide clear current-period revenue, net income, operating cash flow, cash balance, liquidity, margins, or consolidated debt balances. Historical and pro forma financial information is incorporated by reference from the proxy statement and Exhibit 99.1.
Material changes versus the prior comparable period
- The business combination closed on September 29, 2023, transforming Anzu into Envoy Medical, Inc.
- Envoy shareholders received 14,999,990 shares of the company’s Class A common stock; the exchange ratio was 0.063603 per Envoy common share.
- The sponsor forfeited 8,010,000 shares of Anzu Class B common stock and 12,500,000 private placement warrants, exchanged 2,500,000 Class B shares for Series A preferred shares, and retained or converted other securities as described in the filing.
- Existing Envoy convertible notes were converted into common stock under their terms, while the Envoy Bridge Note resulted in the issuance of 1,000,000 Series A preferred shares.
- Common stock and warrants began trading on Nasdaq under COCH and COCHW, respectively, on October 2, 2023. The Series A preferred stock is not publicly traded.
- The company adopted a new certificate of incorporation, amended and restated bylaws, and a certificate of designation for Series A preferred stock.
- Brent Lucas became Chief Executive Officer and David R. Wells became Chief Financial Officer. Charles Brynelsen became board chair, and seven directors were elected.
Outlook, risks, contingencies, and unusual items
- The filing provides no quantitative financial guidance or operating forecast.
- Management cautions that future results depend on medical-device regulatory approvals, clinical development, competition, product commercialization, supplier and manufacturing continuity, intellectual-property protection, financing availability, and the ability to realize the expected benefits of the combination.
- Additional risks include interest-rate and inflation changes, litigation and regulatory proceedings, Nasdaq listing compliance, catastrophic events, and volatility in the post-combination stock price.
- One sponsor-held common share tranche is unvested and subject to forfeiture, with vesting tied to FDA approval of the Acclaim product or a change of control.
- The company entered into registration-rights and lock-up arrangements, indemnification agreements for directors and officers, and new equity incentive and employee stock purchase plans.
- Forward-looking statements are subject to substantial uncertainty, and the company disclaims any obligation to update them except as required by law.
Facts an investor should verify
- Review Exhibit 99.1 and the incorporated proxy-statement financial statements for cash, operating losses, cash burn, debt, and pro forma capitalization.
- Confirm the economic terms, conversion mechanics, liquidation preferences, and potential dilution of the 4,500,000 Series A preferred shares.
- Assess dilution from the 14,166,666 warrants, preferred-share conversions, equity plans, and any unvested sponsor shares.
- Verify the amount of net cash retained after the approximately $25.0 million redemptions, transaction expenses, and financing-related issuances.
- Evaluate the timing and probability of FDA approval and commercialization of the Acclaim product.
- Review the registration-rights, lock-up, sponsor forfeiture, and related-party arrangements for potential selling pressure or governance effects.